Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, October 4, 2019
[ Fri, Oct 04th 2019
] - WOPRAI
[ Fri, Oct 04th 2019
] - WOPRAI
[ Fri, Oct 04th 2019
] - WOPRAI
[ Fri, Oct 04th 2019
] - WOPRAI
[ Fri, Oct 04th 2019
] - WOPRAI
[ Fri, Oct 04th 2019
] - WOPRAI
Thu, October 3, 2019
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
[ Thu, Oct 03rd 2019
] - WOPRAI
Joel Beatty Initiated (ARWR) at Buy and Held Target at $39 on, Oct 3rd, 2019
Joel Beatty of Baird, Initiated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Buy and Held Target at $39 on, Oct 3rd, 2019.
Joel has made no other calls on ARWR in the last 4 months.
There are 2 other peers that have a rating on ARWR. Out of the 2 peers that are also analyzing ARWR, 1 agrees with Joel's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Elemer Piros of "Cantor Fitzgerald" Downgraded from Buy to Hold on, Friday, June 28th, 2019
This is the rating of the analyst that currently disagrees with Joel
- Madhu Kumar of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $46 on, Monday, August 19th, 2019
